Vladimir Badmaev | Pharma | Industry Impact Award

Posted on by ScienceFather

Dr. Vladimir Badmaev  –  Pharma  –  Industry Impact Award

Alignment with Award Category

Dr. Badmaev’s research and innovations align seamlessly with the Industry Impact Award criteria. His pioneering work in natural pharma and smart drug development, along with his numerous patents and product contributions, make him a highly deserving candidate.

American Medical Holdings Inc. | United States

Profile

Orcid

Scopus

🎓Early Academic Pursuits 

Education and Training

Vladimir Badmaev, MD, PhD, embarked on his academic journey at the Medical Academy of Bialystok (AMB) in Poland, where he graduated in 1975. His early academic years laid a strong foundation in medical sciences, leading him to specialize in clinical and anatomical pathology. He pursued his specialization at Kings County Hospital, New York, and Downstate Medical Center, New York, between 1982 and 1985. During this period, he honed his expertise in understanding disease mechanisms and diagnostic techniques. Additionally, in 1978, he obtained his PhD in immunopharmacology from AMB, reflecting his deep interest in the interaction between the immune system and pharmacological agents. His academic credentials positioned him as a leader in integrative medicine, combining traditional knowledge with scientific advancements.

💼Professional Endeavors 

Academic Positions

Dr. Badmaev’s professional career has been defined by his dedication to bridging traditional botanical medicine with modern pharmacological science. In 1984, he established the Badmaev Natural Drug Foundation, an organization committed to exploring the therapeutic potential of natural compounds. Later, in 2009, he founded American Medical Holdings Inc. in Staten Island, New York, to advance the development of nutraceuticals and natural pharmaceutical products. Through these initiatives, he has played a crucial role in integrating the principles of traditional medicine with contemporary scientific research. His company, www.badmaevtradition.com, stands as a testament to his lifelong commitment to safe and effective alternative medicine solutions.

📚Contributions and Research Focus on Pharma

Dr. Badmaev has dedicated his career to the research and development of nutraceuticals and natural pharmaceutical products. He conceptualized the Interactive Nutrients Process (INP), a method that integrates the knowledge of botanicals with pharmacological science to develop “smart drugs” using artificial intelligence. His work has been instrumental in the advancement of various nutraceutical formulations, including C3Complex® (Sabinsa), Gugulipid® (Sabinsa), SeleniumSelect® (Sabinsa), Lactospore® (Sabinsa), Xanthigen® (PLThomas), RhodioLife® (PLThomas/Polyphenoles Naturales), Zembrin® (PLThomas/HGH), 5-Loxin®/Apres-Flex® (PLThomas), and MenaQ7® (NattoPharma). Furthermore, he has been actively involved in developing natural therapeutics such as Adaptrin®, GreenSelenium®, TurmericImmune®, SlimTrym®, and FB3® under American Medical Holdings Inc. His recent work focuses on the natural ginger phenolic derivative, 6-Shogaol, for managing iron overload and early-stage myelodysplastic syndromes (MDS). This breakthrough has resulted in a US patent, No.: US 10,864,174 B2 (2017), along with 11 related patents worldwide (2017-2024).

🏆Accolades and Recognition 

Between 1999 and 2009, Dr. Badmaev was the runner-up or recipient of four New Jersey R&D Council Thomas Alva Edison Awards. These accolades were awarded in recognition of his contributions to scientific research and patent innovations, including US patents #5,536,506, #5,804,596, #6,849,645, and #7,063,861. His extensive work in the field of nutraceutical research has earned him international recognition, leading to collaborations and multiple patent approvals in various countries, including Australia, Canada, New Zealand, Mexico, Brazil, South Africa, the European Community, Japan, Korea, India, and China.

🌍 Impact and Influence 

Community Impact

Dr. Badmaev’s influence extends beyond research and development. His contributions to literature have enriched the understanding of traditional medicine’s integration with modern healthcare. In 1999, he authored a chapter on Tibetan medicine in a medical textbook for students and healthcare professionals, edited by Wayne Jonas and Jeffrey Levine. A decade later, in 2009, he contributed to a chapter on curcuminoids in a book on alternative treatments in medicine by Raymond Cooper and Fredi Kronenberg. His scholarly work has provided valuable insights into the therapeutic applications of botanical medicine.

🔮Legacy and Future Contributions 

Dr. Badmaev’s contributions have left a lasting impact on the field of integrative medicine. His membership in esteemed medical and scientific societies, including the International Society of Immunopharmacology (1982), the American Association of Clinical Pathologists (1983), the American Medical Association (1984), and the Research and Development Council of New Jersey (1996), underscores his commitment to advancing medical science. His ongoing research into the development of AI-driven “smart drugs” signifies his vision for the future of medicine.

 

Conclusion

Vladimir Badmaev, MD, PhD, has dedicated his career to harmonizing traditional botanical medicine with scientific innovation. His pioneering research, extensive patent portfolio, and contributions to the nutraceutical industry exemplify his lifelong mission to develop safe and effective medical solutions. As he continues his work on AI-integrated nutraceuticals, his legacy serves as an inspiration for future generations in the field of integrative medicine.

📚Publications

Interactive Nutrient Process (INP) in a Generative AI of a New Drug—6-Shogaol as a Potential Case

Authors: Vladimir Badmaev

Journals: Drug Design, Development and Therapy

Vitamin K Insufficiency in the Indian Population: Pilot Observational Epidemiology Study

Authors: Rama Vaidya; Ashok D B Vaidya; Jayesh Sheth; Shashank Jadhav; Umakant Mahale; Dilip Mehta; Janusz Popko; Vladimir Badmaev; Sidney J Stohs

Journals: JMIR Public Health and Surveillance

Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review

Authors: Soo Liang Ooi; Ron Campbell; Sok Cheon Pak; Terry Golombick; Arumugam Manoharan; Raj Ramakrishna; Vladimir Badmaev; Janet Schloss

Journals: Integrative Cancer Therapies

Proof‐of‐Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase‐4 in Cognitively Healthy Subjects: Implications for Alzheimer’s Dementia

Authors: Simon Chiu; Nigel Gericke; Michel Farina-Woodbury; Vladimir Badmaev; Hana Raheb; Kristen Terpstra; Joalex Antongiorgi; Yves Bureau; Zack Cernovsky; Jirui Hou et al.

Journals: Evidence-Based Complementary and Alternative Medicine

Jen-Chih Chi | Biotech | Best Researcher Award

Posted on by ScienceFather

Dr.Jen-Chih Chi – Biotech – Best Researcher Award

BeiGene | Taiwan

Author Profile 

Early Academic Pursuits

His academic journey began at the National Cheng Kung University (NCKU) in Taiwan, where he earned his Bachelor’s degree in Chemical Engineering (1999-2003) and later a Master’s degree in Biochemistry and Molecular Biology (2003-2005). His thirst for knowledge and research led him to the University of Cologne in Germany, where he completed his Ph.D. in Biochemistry with magna cum laude honors (2008-2012). During his doctoral studies, Chi was awarded the prestigious fellowship from the Graduate School for Biological Sciences, marking the beginning of a distinguished academic career. Following his Ph.D., he undertook a postdoctoral fellowship at the University of Cologne in 2013, further honing his research skills and laying the groundwork for his future endeavors in cell therapy and bioprocess development.

 

Professional Endeavors

His professional career is marked by significant contributions to the field of cell therapy and bioprocess development. His extensive experience spans multiple high-profile roles in leading biopharmaceutical companies. At BeiGene, Ltd., where he currently serves as the Director of Cell Therapy CMC, Chi has played a crucial role in cell therapy research development and manufacturing. His responsibilities include evaluating cell therapy portfolios, establishing CMC strategies for IND and clinical phase I material production, and managing a development team focused on T cell processing, analytical science, quality control, and cGMP manufacturing.

 

Contributions and Research Focus on Biotech

His research focus spans cell therapy, bioprocess development, and cGMP manufacturing. His core expertise includes biologics/ cell therapy CMC management, asset technical evaluation, project management, drug substance/product process development, and IND-enabling activities. His contributions to cell therapy research and bioprocess technology have been instrumental in bridging knowledge among process scales and phase-appropriate requirements, ensuring efficient delivery and high-performance outcomes.

He has led multiple biologics CMC projects, involving rigorous due diligence, proof of concept (POC) in continuous manufacturing processes, and implementation of process analytical technology. His leadership has been recognized in high-impact publications, including studies on continuous multi-column capture for monoclonal antibodies and the molecular mechanisms of nitrate reductase inhibition.

Accolades and Recognition

His achievements have earned him several honors and awards. He has been an invited speaker at prestigious conferences, such as the NMPAIED in 2022 and the Chinese Chemical Society in 2018. His leadership skills were also evident during his tenure as the Chairman of the Taiwanese Students’ Union in Cologne (2010-2011). His research excellence has been highlighted through a Ph.D. fellowship at the University of Cologne and notable publications in high-impact journals like the Journal of Biological Chemistry and Biochemistry.

Impact and Influence

His work has significantly impacted the biopharmaceutical industry, particularly in the areas of cell therapy and bioprocess development. His contributions have enhanced the efficiency of drug substance production, ensured regulatory compliance, and facilitated the successful delivery of clinical trial materials. His innovative approach to combining scientific research with manufacturing technical operations has set new standards in the industry, fostering cross-functional cooperation and driving advancements in cell therapy and bioprocess technology.

Legacy and Future Contributions

Looking ahead, His legacy is poised to inspire future generations of scientists and professionals in the biopharmaceutical industry. His commitment to innovation, excellence, and sustainability in cell therapy and bioprocess development will continue to influence the field. Chi’s ongoing research and development efforts promise to yield new breakthroughs in cell therapy, offering hope for improved treatments and better patient outcomes. His work serves as a testament to the power of combining rigorous scientific research with practical manufacturing expertise, paving the way for future advancements in biotechnology.

Notable Publications 

Analytical Method Optimization of Sub-Visible Particles in High Concentration Antibody Drug Products and Operation Strategy

Effect of Different Sample Treatment Methods on Low Endotoxin Recovery Phenomenon

Dual Binding of 14-3-3 Protein Regulates Arabidopsis Nitrate Reductase Activity

Molecular Mechanism of 14-3-3 Protein-Mediated Inhibition of Plant Nitrate Reductase

Kinetic Analysis of 14-3-3-Inhibited Arabidopsis Thaliana Nitrate Reductase